For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

OpenAI CEO Sam Altman and Meta both announced $1 million donations, and Amazon and Apple CEO Tim Cook have also reportedly ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...

President-elect Donald Trump has chosen two prominent men to lead health-related affairs in his administration, Mehmet Oz, MD, and Robert Kennedy, Jr. While the two leaders will be leading health ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.

Mount Sinai researchers discovered that harmine, a beta cell regenerative drug, may transform alpha cells into beta cells, ...